FIELD: medicine, pharmaceutics.
SUBSTANCE: what is presented is a group of inventions involving a pharmaceutical composition for preventing or treating diabetes mellitus, diseases related to diabetes mellitus, or complications of diabetes mellitus containing a combination of (A) (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol, or its salt, hydrate or hydrate salt, and (B) metformine or an agent intensifying insulin secretion, and a combination of the same formulation and for the same application.
EFFECT: in addition to the pronounced blood plasma glucose reduction, the synergetic effect is ensured in inhibiting the plasma insulin level; what is also shown is inhibiting the side effect of glimepiride that is a body weight increase.
16 cl, 20 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF DIACEREIN APPLICATION IN ADDITIONAL TREATMENT OF DIABETES | 2011 |
|
RU2563988C2 |
| PHARMACEUTICAL COMBINATION CONTAINING SGLT2 INHIBITOR | 2008 |
|
RU2489151C2 |
| METHOD OF TREATING HYPERGLYCAEMIA | 2017 |
|
RU2739255C2 |
| PANCREATIC DIABETES DRUG | 2004 |
|
RU2358738C2 |
| APPLICATION OF SIBUTRAMIN ANALOGS FOR PREVENTING DIABETES MELLITUS | 1997 |
|
RU2245709C2 |
| SYNERGETIC PHARMACEUTICAL COMPOSITION FOR PROPHYLAXIS AND TREATMENT OF DIABETES MELLITUS | 2002 |
|
RU2311907C2 |
| PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF DIABETES MELLITUS AND OBESITY CONTAINING COMPOUND INHIBITING ACTIVITY OF DIPEPTIDYLPEPTIDASE-IV, AND OTHER ANTIDIABETIC AGENTS OR ANTIOBESITY AGENTS AS ACTIVE INGREDIENTS | 2009 |
|
RU2466727C1 |
| METHOD OF IMPROVEMENT OF LIVER FUNCTION | 2013 |
|
RU2653478C2 |
| APPLICATION OF 3-HYDROXY-3-METHTYLGLUTARYL-COENZYME A REDUCTASE INHIBITORS IN PRODUCING MEDICINAL AGENT FOR TREATMENT OF DIABETIC NEUROPATHY | 2000 |
|
RU2239456C2 |
| COMBINATION FOR TREATMENT OF DIABETES AND COMPLICATIONS THEREOF | 2011 |
|
RU2451506C1 |
